Movement Alert｜CVS Health Rises 3.39% in Pre-Market Trading, FTC Settlement Removes Major Regulatory Overhang

Market Focus07-16 18:07

On July 16, CVS Health rose 3.39% in pre-market trading, trading at $108.50/share, with turnover of $225,300.

The move follows CVS Caremark's announcement of a global settlement with the Federal Trade Commission, resolving all outstanding FTC litigation and investigations related to rebate practices, pharmacy network contracting, and vertical integration issues. The agreement aligns with CVS Caremark's existing affordability and transparency initiatives, including point-of-sale rebate options, flat-dollar copays, copay caps, $0 preventive drug lists, and the TrueCost pricing model.

The settlement eliminates a significant source of regulatory uncertainty that had weighed on the stock. Additionally, multiple Wall Street firms recently raised price targets on CVS Health, including Wells Fargo to $123, Leerink Partners to $119, Goldman Sachs to $116, and RBC to $113, all maintaining bullish ratings. The consensus mean target now stands at approximately $109.96, reflecting growing confidence in the company's turnaround trajectory following consecutive earnings beats and raised guidance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1178647354?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-16 18:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178647354","market":"us","top_or_hot":-1,"title":"Movement Alert｜CVS Health Rises 3.39% in Pre-Market Trading, FTC Settlement Removes Major Regulatory Overhang","media":"Market Focus","content":"<p style=\"text-align: left;\">On July 16, CVS Health rose 3.39% in pre-market trading, trading at $108.50/share, with turnover of $225,300.</p><p style=\"text-align: left;\">The move follows CVS Caremark's announcement of a global settlement with the Federal Trade Commission, resolving all outstanding FTC litigation and investigations related to rebate practices, pharmacy network contracting, and vertical integration issues. The agreement aligns with CVS Caremark's existing affordability and transparency initiatives, including point-of-sale rebate options, flat-dollar copays, copay caps, $0 preventive drug lists, and the TrueCost pricing model.</p><p style=\"text-align: left;\">The settlement eliminates a significant source of regulatory uncertainty that had weighed on the stock. Additionally, multiple Wall Street firms recently raised price targets on CVS Health, including Wells Fargo to $123, Leerink Partners to $119, Goldman Sachs to $116, and RBC to $113, all maintaining bullish ratings. The consensus mean target now stands at approximately $109.96, reflecting growing confidence in the company's turnaround trajectory following consecutive earnings beats and raised guidance.</p><p style=\"text-align: left;\">(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CVS Health Rises 3.39% in Pre-Market Trading, FTC Settlement Removes Major Regulatory Overhang</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CVS Health Rises 3.39% in Pre-Market Trading, FTC Settlement Removes Major Regulatory Overhang\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-16 18:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p style=\"text-align: left;\">On July 16, CVS Health rose 3.39% in pre-market trading, trading at $108.50/share, with turnover of $225,300.</p><p style=\"text-align: left;\">The move follows CVS Caremark's announcement of a global settlement with the Federal Trade Commission, resolving all outstanding FTC litigation and investigations related to rebate practices, pharmacy network contracting, and vertical integration issues. The agreement aligns with CVS Caremark's existing affordability and transparency initiatives, including point-of-sale rebate options, flat-dollar copays, copay caps, $0 preventive drug lists, and the TrueCost pricing model.</p><p style=\"text-align: left;\">The settlement eliminates a significant source of regulatory uncertainty that had weighed on the stock. Additionally, multiple Wall Street firms recently raised price targets on CVS Health, including Wells Fargo to $123, Leerink Partners to $119, Goldman Sachs to $116, and RBC to $113, all maintaining bullish ratings. The consensus mean target now stands at approximately $109.96, reflecting growing confidence in the company's turnaround trajectory following consecutive earnings beats and raised guidance.</p><p style=\"text-align: left;\">(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CVS","symbol_name":"西维斯健康","start_time":0,"source_url":"","article_id":"1178647354","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178647354","pubTimestamp":1784196427,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 16, CVS Health rose 3.39% in pre-market trading, trading at $108.50/share, with turnover of $225,300.The move follows CVS Caremark's announcement of a global settlement with the Federal Trade...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CVS":"西维斯健康"},"translate_title":"走势警报|CVS Health 盘前交易上涨 3.39%，FTC 和解消除了重大监管问题","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CVS":1},"content_text":"On July 16, CVS Health rose 3.39% in pre-market trading, trading at $108.50/share, with turnover of $225,300.The move follows CVS Caremark's announcement of a global settlement with the Federal Trade Commission, resolving all outstanding FTC litigation and investigations related to rebate practices, pharmacy network contracting, and vertical integration issues. The agreement aligns with CVS Caremark's existing affordability and transparency initiatives, including point-of-sale rebate options, flat-dollar copays, copay caps, $0 preventive drug lists, and the TrueCost pricing model.The settlement eliminates a significant source of regulatory uncertainty that had weighed on the stock. Additionally, multiple Wall Street firms recently raised price targets on CVS Health, including Wells Fargo to $123, Leerink Partners to $119, Goldman Sachs to $116, and RBC to $113, all maintaining bullish ratings. The consensus mean target now stands at approximately $109.96, reflecting growing confidence in the company's turnaround trajectory following consecutive earnings beats and raised guidance.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1178647354","isCrawlerRequest":true}